Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A-443654 是 pan-Akt 抑制剂,对Akt1,Akt2,和Akt3具有同等效力的抑制作用,Ki=均为 160 pM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 663 | 现货 | ||
5 mg | ¥ 1,660 | 现货 | ||
10 mg | ¥ 2,590 | 现货 | ||
25 mg | ¥ 4,790 | 现货 | ||
50 mg | ¥ 7,320 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
200 mg | ¥ 13,300 | 现货 | ||
500 mg | ¥ 19,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,830 | 现货 |
产品描述 | A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM). |
靶点活性 | CK2:2.4 μM (ki), Chk1:2.3 μM (ki), c-Kit:1.2 μM (ki), ERK2:340 nM (ki), Akt3:160 pM (ki), PKCδ:33 nM (ki), PKCγ:24 nM (ki), MAPK-AP2:3.3 μM (ki), KDR:3.1 μM (ki), PKA:6.3 nM (ki), CDK2:24 nM (ki), RSK2:11 nM (ki), Akt2:160 pM (ki), Src:2.6 μM (ki), Akt1:160 pM (ki), GSK-3β:41 nM (ki) |
体外活性 | A-443654 exhibits a Ki of 160 pM which is a 30,000-fold improvement in potency versus the initial lead molecule. A-443654 reduces the P-GSK3 in a dose-responsive manner in all three cell lines. A-443654 is 40-fold selective for Akt over PKA, and it inhibits Akt1, Akt2, or Akt3 equally within cells. A-443654-induced morphological changes occur very rapidly (within 2 to 4 h) in both 10A and 10CA1a cells, with 10CA1a cells more sensitive to A-443654 than the 10A cells. A-443654 inhibits the proliferation of tumor cells with EC50 of 0.1 μM[1]. A-443654 demonstrates the greatest selective effect on the mutant cells compared to the WT cells with greater than 3.5 fold relative growth inhibition of the mutant cells[3]. FACScan Analysis of rapamycin and A-443654 effects on DNA content in 10A and 10CA1a cells. In contrast, A-443654 at 2 and 5 μM decreases Bcl-2 levels by 30 to 40% in the 10CA1a cells at 8h. The combination of rapamycin with 2 or 5 μM A-443654, however, markedly decreases Bcl-2 protein levels by appr 40 to 50% in the 10A cells and by appr 70% in the 10CA1a cells, respectively. A-443654 alone at 2 μM causes the 10CA1a cells, but not the 10A cells, to detach from the plate after 12 h, whereas 1 μM of A-443654 causes 10CA1a cells to detach from the plate after 12 h [2]. |
体内活性 | A-443654 (7.5 mg/kg/d, s.c.) inhibits tumor growth in the 3T3-Akt1 flank tumor model. A-443654 (30 mg/kg, s.c.) caused increased levels of phosphorylated Akt1 in MiaPaCa-2 tumors. A-443654 (50 mg/kg, s.c.) induces apoptosis in 3T3-Akt1 flank tumors [1]. |
分子量 | 397.47 |
分子式 | C24H23N5O |
CAS No. | 552325-16-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (251.59 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5159 mL | 12.5796 mL | 25.1591 mL | 62.8978 mL |
5 mM | 0.5032 mL | 2.5159 mL | 5.0318 mL | 12.5796 mL | |
10 mM | 0.2516 mL | 1.258 mL | 2.5159 mL | 6.2898 mL | |
20 mM | 0.1258 mL | 0.629 mL | 1.258 mL | 3.1449 mL | |
50 mM | 0.0503 mL | 0.2516 mL | 0.5032 mL | 1.258 mL | |
100 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.629 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
A-443654 552325-16-3 Angiogenesis Cell Cycle/Checkpoint Chromatin/Epigenetic Cytoskeletal Signaling MAPK Metabolism PI3K/Akt/mTOR signaling Stem Cells Tyrosine Kinase/Adaptors ERK VEGFR GSK-3 FLT Casein Kinase Akt PKA Chk CDK Src PKC S6 Kinase A443654 inhibit A 443654 Inhibitor PKB Protein kinase B inhibitor